Mitochondrial Dysfunction and NAD Supplementation

Mitochondrial dysfunction is a central feature of aging, marked by both a decline in mitochondrial number and quality. This process is driven by several interconnected mechanisms, including decreased mitochondrial formation, accumulation of genetic mutations, increased oxidative stress, accumulation of dysfunctional mitochondria, and morphological changes in which mitochondria often become swollen, fragmented, and less able to maintain normal structure and function. It would therefore stand to reason that by slowing or even reversal of this dysfunction we could hinder the process of aging.

So what evidence is there currently for effective measures to reduce mitochondrial dysfunction? Despite this seemingly a holy-grail of anti-aging, the evidence is sadly quite sparse.

Non-Pharmacologic Measures:

• Exercise: Regular physical activity, especially high-intensity interval training (HIIT) and resistance training, robustly stimulates mitochondrial biogenesis and improves mitochondrial function in older adults.
• Caloric Restriction (CR): CR (by means of intermittent fasting, for example) has consistently been shown to enhance mitochondrial function and reduce oxidative damage in animal models and humans.
• Dietary Modifications: Diets rich in antioxidants and certain nutrients may support mitochondrial health, although evidence is less robust than for exercise and caloric restriction.

Pharmacologic and Peptide-Based Approaches:

• NAD+ Precursors: Supplementation with NAD+ precursors (e.g., nicotinamide riboside and nicotinamide mononucleotide) has been shown in animal models to restore mitophagy, improve mitochondrial function, and extend healthspan. More on this later.
• Mitophagy Activators: Compounds that activate mitophagy pathways (e.g., targeting PINK1, Parkin, USP30) are under investigation and show promise in preclinical studies but not commercially available.
• PGC-1α Activators: Small molecules that stimulate mitochondrial biogenesis via PGC-1α are being explored, though most research is also still preclinical.
• Peptides: Mitochondria-targeted peptides (such as SS-31/elamipretide) have shown efficacy in animal models and early human trials, improving mitochondrial function and reducing oxidative stress, but large-scale clinical outcome data are still limited.
• Hormonal Modulation: Hormones like thyroid hormone, estrogen, and glucocorticoids influence mitochondrial biogenesis, and their decline with age may contribute to mitochondrial dysfunction. Hormone replacement therapy and treatment of metabolic disorder can therefore hinder this process.

NAD Supplementation:

Given its status as among the most readily accessible therapeutic options presently available, this intervention generates the highest volume of patient inquiries. I therefore present here a review of supplementation approaches and analysis of the current scientific evidence.

Oral NAD+ Precursors (NR and NMN)

Efficacy and Safety:

• Both NR and NMN consistently increase blood NAD+ levels in healthy adults and older populations, with dose-dependent effects and generally good safety profiles.
• Short-term studies (typically 3–12 weeks) show that NR and NMN are well tolerated, with only mild side effects (e.g., GI upset, rashes, fatigue) and no serious adverse events. NR is recognized as safe by the US FDA and other regulatory agencies.

Clinical Outcomes:

• Some small trials show improvements in physical performance, muscle strength, insulin sensitivity (especially in overweight or prediabetic individuals), and cardiovascular/metabolic markers.
• Most studies in healthy individuals do not show significant improvements in clinical endpoints such as blood pressure, body weight, or metabolic health.
• Larger, well-powered trials are lacking. Most published studies are small, short-term, and often focus on surrogate markers or safety rather than hard clinical outcomes.

Notable Results:

• In overweight/obese postmenopausal women with prediabetes, NMN improved muscle insulin signaling and some metabolic parameters.
• In healthy older adults, NMN and NR improved some measures of physical performance (e.g., grip strength, walking distance), but these findings are not universal and need confirmation in larger trials.

Intravenous (IV) and Intramuscular (IM) NAD+ Administration

Evidence Base:

• Much less studied than oral precursors. Only a handful of clinical trials have evaluated IV or IM NAD+ administration.
• In a small trial of IV NADH for 10–14 days in patients with chronic fatigue syndrome, about 62% showed significant improvement in disability, but this was an open-label study with no placebo control.
• Pharmacokinetics are unclear: IV NAD+ is likely rapidly degraded in the liver and bloodstream, and it is not well established how much reaches tissues intact5.
• No large, well-controlled trials exist for IV/IM NAD+ in aging or chronic disease populations.

Limitations and Concerns:

• Long-term safety is unknown: No long-term human trials have been completed for either oral or parenteral NAD+ supplementation.
• Potential adverse effects: Some animal studies suggest high doses could impair glucose metabolism or have other metabolic effects, but this has not been clearly demonstrated in humans.
• Limited evidence for clinical benefit: While NAD+ boosters reliably increase NAD+ levels, evidence for meaningful clinical improvements in healthy populations is weak; benefits may be more likely in those with metabolic dysfunction or age-related decline.

Conclusion

Oral NR and NMN supplementation reliably increase NAD+ levels and are safe in the short term, with some evidence for clinical benefit in specific populations only (e.g., metabolic dysfunction, older adults), but robust, long-term clinical outcome data are lacking. IV/IM NAD+ is less studied, with unclear pharmacokinetics and minimal clinical evidence. Larger, longer, and well-controlled trials are needed to establish efficacy and safety for both routes, especially regarding meaningful clinical outcomes in aging and disease.

Bibliography

1. Srivastava, S. (2017). The Mitochondrial Basis of Aging and Age-Related Disorders. Genes (Basel), 8(12), 398. https://doi.org/10.3390/genes8120398 15
2. Guo, Y., Guan, T., Shafiq, K., Yu, Q., Jiao, X., Na, D., Li, M., Zhang, G., & Kong, J. (2023). Mitochondrial dysfunction in aging. Ageing Research Reviews, 88, 101955. https://doi.org/10.1016/j.arr.2023.101955 7
3. Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022). Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduction and Targeted Therapy, 7, Article 391. https://doi.org/10.1038/s41392-022-01251-0
4. Duran, J., Martinez, A., & Adler, E. (2019). Mitochondrial Dysfunction in Aging and Diseases of Aging. Frontiers in Physiology, Special Edition. https://pmc.ncbi.nlm.nih.gov/articles/PMC6627182/ 3
5. Elfawy, H.A., et al. (2023). Mitochondrial dysfunction in aging. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. https://www.sciencedirect.com/science/article/abs/pii/S1568163723001149 4
6. Miwa, S., Kashyap, S., Chini, E., & von Zglinicki, T. (2022). Mitochondrial dysfunction in cell senescence and aging. Journal of Clinical Investigation, 132(13), e158447. https://doi.org/10.1172/JCI158447 6
7. Kolhapur Institute of Technology’s College of Engineering et al. (2024). Mitochondrial dysfunction and its association with age-related disorders. Frontiers in Physiology, 15, 1384966. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2024.1384966/full 2